Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 16/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 15/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6006710 | 1.00 | PGR (0.56) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL3995591 | 0.89 | PGR (0.57) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL14079651 | 0.88 | PGR (0.47) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL4590511 | 0.88 | PGR (0.47) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL14099900 | 0.87 | PGR (0.49) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL14079652 | 0.87 | PGR (0.47) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL14079653 | 0.86 | PGR (0.47) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL4589637 | 0.86 | PGR (0.47) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL14079664 | 0.86 | PGR (0.49) | PGRNR3C1NR3C2MEN1KMT2A | |
| SCHEMBL14079666 | 0.86 | PGR (0.47) | PGRNR3C1NR3C2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234240-A1 | Extended Use Combination Comprising Estrogens And Progestins | SCHERING AG (DE) | 2008-09-25 | — | — | US | claimed |
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | claimed |
| JP-2007512291-A | — | — | 2007-05-17 | — | — | JP | claimed |
| EP-1482925-B1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL]-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2007-01-17 | — | — | EP | claimed |
| EP-1689409-A1 | PHARMACEUTICAL PREPARATION FOR CONTINUOUS HORMONAL TREATMENT OVER A PERIOD OF LONGER THAN 21-28 DAYS COMPRISING TWO ESTROGEN AND/OR PROGESTIN COMPOSITIONS | Schering Aktiengesellschaft (DE) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051400-A1 | EXTENDED USE COMBINATION COMPRISING ESTROGENS AND PROGESTINS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-09 | — | — | WO | claimed |
| EP-1535618-A1 | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions | Schering Aktiengesellschaft (DE) | 2005-06-01 | — | — | EP | claimed |
| US-20050113350-A1 | Extended use combination comprising estrogens and progestins | DUESTERBERG BERND (DE) | 2005-05-26 | — | — | US | claimed |
| EP-1482925-A1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL!-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | Schering AG (DE) | 2004-12-08 | — | — | EP | claimed |
| US-20030232824-A1 | Non-steroidal progesting | SCHERING AG (DE) | 2003-12-18 | — | — | US | claimed |
| WO-2003075915-A1 | 5-}2-HYDROXY-3-`1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPYL!-PROPIONYLAMINO}- PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2003-09-18 | — | — | WO | claimed |
| EP-1344776-A1 | 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders | Schering Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | claimed |
| EP-2044942-A1 | Pharmaceutical preparation for continuous hormonal treatment over a period of 21-28 days comprising two ethinylestradio or estradio and drospirenone compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080234240-A1 | Extended Use Combination Comprising Estrogens And Progestins | SCHERING AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | disclosed |
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | disclosed |
| EP-1482925-A1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL!-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | Schering AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20030232824-A1 | Non-steroidal progesting | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003075915-A1 | 5-}2-HYDROXY-3-`1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPYL!-PROPIONYLAMINO}- PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| EP-1344776-A1 | 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders | Schering Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232824-A1 | Non-steroidal progesting | PGR, NR5A1, GPER1 | PGR 1/4885NR3C1 13/4885NR3C2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.